Mind Medicine (MNMD) has released an update.
Mind Medicine (MindMed) Inc. has secured a new US patent for their MM120 Orally Disintegrating Tablet (ODT), a lysergide-based treatment for anxiety and other brain health disorders, with protection extended until 2041. The patent covers the formulation, manufacturing, and treatment methods of MM120, which offers potential pharmacological benefits such as rapid absorption and reduced side effects through the use of Catalent’s Zydis technology.
For further insights into MNMD stock, check out TipRanks’ Stock Analysis page.
